Creating Value by Investing in Tomorrow, Today.

Dear Shareholders

“It has been an exhilarating first year for me as Organovo’s CEO. We have evolved the way we define ourselves and how we bring the value of our platform technology to customers and future patients.”
Taylor J. Crouch, President and Chief Executive Officer

Multiple Paths for Creating Value

Therapeutic Tissues

We are developing our liver tissue to treat a range of rare, life-threatening diseases for which there are limited treatment options. Our goal is to delay or reduce the need for an organ transplant, while also reducing the annual cost of care for patients. Our strategy envisions our NovoTissues® being able to treat multiple disease areas, offering significant research, manufacturing and developmental benefits.

Drug Profiling Capabilities

We are harnessing our foundational ability to characterize specialized human cells and to 3D bioprint functional human tissues to create novel liver disease modeling platforms. We expect that our platforms will be increasingly accessed by our clients through collaborative, revenue-generating agreements.

  1. 1 Therapeutic Tissues
  2. 2 High-Quality Human Cells (Samsara)
  3. 3 Disease Modeling Platform Supports Drug Discovery & Development


We facilitate a better understanding of disease processes, the discovery of novel therapeutics, and the safety assessment of drugs in a disease-relevant background.

Our 3D bioprinting platform enables the creation of durable, multi-cellular tissues with complex architecture that replicates key aspects of native biology.

The global biopharma industry has launched more than 250 clinical therapeutic programs to pursue treatments across the liver disease spectrum including NASH.

We have seen great revenue traction from our Samsara division, which more than tripled its contribution to our business during fiscal 2018.

We have the potential to provide our customers with essentially a lab to human translation, which we believe can greatly improve the effectiveness of drug research.


We are targeting submission of our first Investigational New Drug Application (IND) in calendar-year 2020.

Liver disease is a growing public health crisis throughout the U.S., Europe and Asia, with approximately one-third of the developed world suffering from deteriorating liver function.

Inborn errors of metabolism such as Alpha-1-antitrypsin deficiency and Type 1 Tyrosinemia represent rare and potentially fatal diseases with great unmet need.

We are building out our IND-track therapeutics programs, having reached our first regulatory milestone in fiscal 2018, with the FDA granting us orphan designation for our first indication.